Cargando…

Development and validation of a novel competing risk model for predicting survival of esophagogastric junction adenocarcinoma: a SEER population-based study and external validation

BACKGROUND: Adenocarcinoma in Esophagogastric Junction (AEG) is a severe gastrointestinal malignancy with a unique clinicopathological feature. Hence, we aimed to develop a competing risk nomogram for predicting survival for AEG patients and compared it with new 8th traditional tumor-node-metastasis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Tongbo, Wu, Yan, Zhou, Hong, Wu, Chaorui, Zhang, Xiaojie, Chen, Yingtai, Zhao, Dongbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836166/ https://www.ncbi.nlm.nih.gov/pubmed/33499821 http://dx.doi.org/10.1186/s12876-021-01618-7

Ejemplares similares

Primary tumor resection and lymph node dissection improve survival in de novo metastatic pancreatic ductal adenocarcinoma: an inverse probability of treatment weighting analysis
por: Wu, Chaorui, et al.
Publicado: (2020)

Neoadjuvant chemotherapy-induced severe neutropenia is associated with histopathological response and survival in locally advanced gastric cancer
por: Wu, Chaorui, et al.
Publicado: (2020)

Impact of the time from the completion of neoadjuvant chemotherapy to surgery on the outcomes of patients with gastric cancer
por: Wu, Chaorui, et al.
Publicado: (2019)

Development and validation of a nomogram to individually predict survival of young patients with nonmetastatic gastric cancer: A retrospective cohort study
por: Wu, Chaorui, et al.
Publicado: (2019)

Clinicopathological Characteristics and Survival Predictions for Adenocarcinoma of the Esophagogastric Junction: A SEER Population-Based Retrospective Study
por: Liu, Xin, et al.
Publicado: (2021)

The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study
por: Wang, Tongbo, et al.
Publicado: (2021)

Better Prognosis of Gastric Neuroendocrine Carcinoma Than Gastric Adenocarcinoma among Whites in the United States: A Propensity Score Matching Analysis Based on SEER
por: Li, Zefeng, et al.
Publicado: (2022)

Nomogram predicted survival of patients with adenocarcinoma of esophagogastric junction
por: Zhou, Zhangjian, et al.
Publicado: (2015)

Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy
por: Zhang, Xiaojie, et al.
Publicado: (2022)

Survival analysis and nomogram for pulmonary sarcomatoid carcinoma: an SEER analysis and external validation
por: Wu, Weishuai, et al.
Publicado: (2023)

Regional and racial disparity in proximal gastric cancer survival outcomes 1996–2016: Results from SEER and China National Cancer Center database
por: Zhao, Lulu, et al.
Publicado: (2021)

Current surgical treatment of esophagogastric junction adenocarcinoma
por: Zhang, Shun, et al.
Publicado: (2019)

Integrative proteomic characterization of adenocarcinoma of esophagogastric junction
por: Li, Shengli, et al.
Publicado: (2023)

Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data
por: Chen, Jian, et al.
Publicado: (2021)

Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction
por: Cai, Ming-Zhi, et al.
Publicado: (2019)

Resection of the Primary Tumor Improves the Survival of Patients With Stage IV Gastric Neuroendocrine Carcinoma
por: Li, Zefeng, et al.
Publicado: (2022)

Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma
por: Li, Haijun, et al.
Publicado: (2017)

Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma
por: Nobel, Tamar, et al.
Publicado: (2019)

Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?
por: Laxague, Francisco, et al.
Publicado: (2021)

Effect of Marital Status on the Survival of Patients With Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Study
por: Wang, Sihan, et al.
Publicado: (2021)

Survival trends and conditional survival in primary non-metastatic esophageal cancer: a SEER population-based study and external validation
por: Sun, Wei, et al.
Publicado: (2023)

Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection
por: Wang, Tongbo, et al.
Publicado: (2020)

Clinicopathological characteristics, survival outcomes, and genetic alterations of younger patients with gastric cancer: Results from the China National Cancer Center and cBioPortal datasets
por: Niu, Penghui, et al.
Publicado: (2022)

Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Comprehensive Analysis of Data from the SEER Registry
por: Zhu, Kaixuan, et al.
Publicado: (2019)

Survival Nomogram for Young Breast Cancer Patients Based on the SEER Database and an External Validation Cohort
por: Huang, Xiao, et al.
Publicado: (2022)

Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China
por: Zhang, Hao, et al.
Publicado: (2013)

Clinical Efficacy of Endoscopic Submucosal Dissection for Adenocarcinomas of the Esophagogastric Junction
por: Nagami, Yasuaki, et al.
Publicado: (2014)

Can proximal Gastrectomy Be Justified for Advanced Adenocarcinoma of the Esophagogastric Junction?
por: Sato, Yuya, et al.
Publicado: (2018)

MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction
por: Just, Christina, et al.
Publicado: (2019)

Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study
por: Xu, Haitao, et al.
Publicado: (2020)

Investigation of BTLA tagging variants with risk of esophagogastric junction adenocarcinoma
por: Tang, Weifeng, et al.
Publicado: (2019)

Analysis of N(6)-Methyladenosine Methylome in Adenocarcinoma of Esophagogastric Junction
por: Huang, Jia-Bin, et al.
Publicado: (2022)

Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction
por: Zheng, Yi-Han, et al.
Publicado: (2022)

Esophagogastric junctional neuroendocrine tumor with adenocarcinoma: A case report
por: Kong, Zhen-Zhen, et al.
Publicado: (2022)

The correlation between the margin of resection and prognosis in esophagogastric junction adenocarcinoma
por: Pang, Tao, et al.
Publicado: (2023)

Survival nomogram for different grades of gastric cancer patients based on SEER database and external validation cohort
por: Hu, Lei, et al.
Publicado: (2022)

Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort
por: Guan, Yelan, et al.
Publicado: (2023)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction
por: Sun, Lidan, et al.
Publicado: (2014)

Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma
por: Xu, Yi-Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gli7elhjj8acbaq0qsgi3aapje